Back to Search Start Over

Studies from Yamagata Prefectural Central Hospital Yield New Information about Lung Cancer (Nivolumab Therapy In Lung Cancer Associated With Igg4-related Disease).

Studies from Yamagata Prefectural Central Hospital Yield New Information about Lung Cancer (Nivolumab Therapy In Lung Cancer Associated With Igg4-related Disease).

Source :
Immunotherapy Weekly; 2024, p1904-1904, 1p
Publication Year :
2024

Abstract

A study conducted at Yamagata Prefectural Central Hospital in Japan explored the use of nivolumab therapy in a 75-year-old man with lung cancer and IgG4-related disease (IgG4-RD). The patient was treated with nivolumab and low-dose prednisolone for 15 months, during which time the IgG4-RD did not relapse and no adverse events occurred. The researchers concluded that anti-programmed cell death protein-1 antibody (nivolumab) may be safely used in lung cancer patients with IgG4-RD, alongside low-dose steroids. This research has been peer-reviewed and published in Internal Medicine. [Extracted from the article]

Details

Language :
English
ISSN :
10908625
Database :
Supplemental Index
Journal :
Immunotherapy Weekly
Publication Type :
Periodical
Accession number :
175606718